Skip to main
AMPH

Amphastar Pharma (AMPH) Stock Forecast & Price Target

Amphastar Pharma (AMPH) Analyst Ratings

Based on 6 analyst ratings
Hold
Strong Buy 17%
Buy 17%
Hold 67%
Sell 0%
Strong Sell 0%

Bulls say

Amphastar Pharmaceuticals Inc. demonstrated a notable increase in Baqsimi sales, with an estimated 20% quarter-over-quarter rise in prescriptions during the third quarter of 2025, driven by a collaboration with MNKD and seasonal trends. The company's strategic expectations of maintaining a flat year-over-year top-line in 2025, followed by a return to double-digit growth in 2026, support a solid long-term outlook. Additionally, strong performance from products like Primatene Mist, particularly anticipated in the fall and winter seasons, further positions Amphastar favorably within the competitive landscape.

Bears say

Amphastar Pharmaceuticals Inc. is facing a significant decline in revenue projections for key products, notably iron sucrose and glucagon, as increased competition from generics is expected to severely impact sales. Specifically, iron sucrose sales, initially anticipated to reach $60 million annually, are now forecasted to generate only about $5 million quarterly due to market saturation and initial supply concerns, while glucagon sales projections have been adjusted downward to below $70 million starting in 2026 as the competitive landscape intensifies. Furthermore, the anticipated recovery in top-line growth expected for 2026 has been re-evaluated, suggesting a shift from double-digit gains to moderate high-single to low-double digit growth, raising further concerns about the company's future financial performance.

Amphastar Pharma (AMPH) has been analyzed by 6 analysts, with a consensus rating of Hold. 17% of analysts recommend a Strong Buy, 17% recommend Buy, 67% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Amphastar Pharma and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Amphastar Pharma (AMPH) Forecast

Analysts have given Amphastar Pharma (AMPH) a Hold based on their latest research and market trends.

According to 6 analysts, Amphastar Pharma (AMPH) has a Hold consensus rating as of Dec 30, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $31, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $31, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Amphastar Pharma (AMPH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.